Home > Resources > Whitepapers > New insight into the genetics, developmental mechanism and therapeutic targets of Retinitis Pigmentosa

New insight into the genetics, developmental mechanism and therapeutic targets of Retinitis Pigmentosa

November 12, 2018

Hereditary degeneration of the human retina is genetically miscellaneous, with more than a hundred genes identified until now. Retinitis pigmentosa (RP) is a group of genetic retinal disorder which results in the degeneration of rods & cones photo-receptor. Retinitis pigmentosa is categorized by moon blindness and gradual loss of peripheral visualization, many time leads to thorough blindness. This disorder is both genetically and clinically heterogeneous. Retinitis pigmentosa could be linked with the syndromic disease as genes important for the retina also play the role in complementary tissues.

Spotlight

UCSB Biotechnology Industry Showcase

The UCSB Biotechnology Showcase is an annual event hosted by UCSB students and faculty which aims to increase awareness among students and researchers on campus about emerging and established biotechnologies. The showcase is also a program used to expose students to the needs and career options of industry and to strengthen relationships among biotechnology industries and UCSB affiliates.

OTHER WHITEPAPERS

Biopharmaceutical Sector

whitePaper | May 29, 2023

tronger than expected US inflation and a bump in consumer spending have fuelled worldwide expectations that interest rates will go higher, as predictions about future monetary policy rapidly shift.

The US Bioeconomy

whitePaper | April 14, 2022

In the nearly 50 years since the first genetic engineering experiments, the United States has become the world’s biotechnology powerhouse,

The affordability hurdle for gene therapies

whitePaper | October 12, 2022

Advanced therapy medicinal products cell and gene therapies offer tremendous hope for patients either by actually curing serious diseases or by alleviating suffering.

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

U.S. Biopharma Expansions to Europe: Ensuring Successful Build-Out & Market Access

whitePaper | May 24, 2023

The Greater Zurich Area Ltd (GZA), Apellis, and Korn Ferry co-hosted a virtual roundtable for a select group of biopharma leaders interested in expanding their operations into Europe. The panel brought together European launch specialists, talent experts, and Swiss government officials to cover critical questions and guiding principles necessary for a successful European launch, as well as insider knowledge of how to best navigate the regulatory environment.

More Whitepapers